Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis
SGLT2i use was associated with reduced risk of fibrotic progression compared to DPP4i use in adults with MASLD and T2DM.
Authors
- Daniel Fulop (ORCID: https://orcid.org/0000-0002-3778-4107)
- Jonggi Choi (ORCID: https://orcid.org/0000-0002-7470-5850)
- Raymond T. Chung (ORCID: https://orcid.org/0000-0003-1338-9564)
- Erik Almazan (ORCID: https://orcid.org/0000-0001-8625-0083)
- Vy H. Nguyen (ORCID: https://orcid.org/0000-0002-9888-8321)
- Allison J. Carroll (ORCID: https://orcid.org/0000-0002-3576-8808)
- Eric M. Przybyszewski (ORCID: https://orcid.org/0000-0001-5664-3361)
- Jiunn Song (ORCID: https://orcid.org/0000-0002-4206-3291)
- Tracey G. Simon (ORCID: https://orcid.org/0000-0003-0610-5287)
- Megan Michta
Institutions
- Ulsan College (KR)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3350/cmh.2025.0825
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00